Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia, II: convergent/discriminant validity and diagnostic group comparisons.
ABSTRACT In a companion article in this issue of the Journal, the authors presented data suggesting that the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) is sensitive to the types of impairments observed in schizophrenia, correlates highly with standard measures of intelligence and memory, and is related to employment status in a group of patients with schizophrenia drawn from a tertiary care research center. The objectives of the current study were 1) to determine if evidence of the convergent validity of the RBANS could be replicated in a diagnostically heterogeneous sample drawn from a public mental health system, 2) to examine the relationship of the RBANS to a broad neuropsychological battery, and 3) to compare the performance of patients with schizophrenia and patients with bipolar disorder on a neuropsychological battery and the RBANS.
The RBANS and a standard neuropsychological battery, including the WAIS-III and Wechsler Memory Scale, 3rd ed. (WMS-III), were given to 150 patients drawn from a larger study of vocational rehabilitation.
Correlations of RBANS total scores with WAIS-III and WMS-III variables were highly similar across study groups. The RBANS correlated highly with a composite z score derived from 22 standard measures of IQ, memory, language, motor, attention, and executive function. Principal component analyses of the neuropsychological battery resulted in a six-factor solution: the RBANS correlated most highly with a general ability factor and had limited correlations with measures of motor performance, vigilance, and executive function. Patients with schizophrenia demonstrated greater deficits on the neuropsychological battery and the RBANS than patients with bipolar disorder.
These data suggest that the RBANS is a useful screening instrument for assessing the severity of cognitive impairment in psychiatric populations.
- SourceAvailable from: Rafidah Bahari[Show abstract] [Hide abstract]
ABSTRACT: Cognitive impairment is a main feature of schizophrenia. Schizophrenia patients demonstrate impairments in several key dimensions of cognitions and these impairments are closely associated with functional outcome. T he importance of cognitive assessment has been broadly accepted today; therefore an easy administered test battery is needed by researchers and in daily clinical practice. T he Brief Assessment of Cognition in Schizophrenia (BACS), a cognitive assessment tool has been validated internationally in English, French, German, Sp anish, Japanese, and Italian. T his prelimin ary study was performed to test the reliability and validity of the Brief Assessment of Cognition in Schizophrenia (BACS) as an assessment tool in a
- [Show abstract] [Hide abstract]
ABSTRACT: Individuals with schizophrenia (SZ) have been reported to exhibit a higher prevalence of convergence insufficiency (CI) than the "normal" adult population. The purpose of this study was to determine if individuals with SZ exhibit clinical signs of CI and to determine if the Convergence Insufficiency Symptom Survey (CISS) is an effective instrument for identifying CI in this population. Twenty participants with SZ and 20 healthy controls (HC) completed the study. The prevalence of CI (15%) in the SZ group was slightly higher than reported norms, but the difference was not significant. The SZ group had significantly higher scores on the CISS than the HC group, but the CISS scores did not correlate with clinical measures of CI in individuals with SZ. The only exception was that SZ patients had a significantly reduced fusional reserve as determined by Sheard's criteria. Further study is needed to determine why individuals with SZ reported symptoms associated with CI even though clinical measures did not support this diagnosis.Frontiers in Psychiatry 10/2012; 3:86. DOI:10.3389/fpsyt.2012.00086
- [Show abstract] [Hide abstract]
ABSTRACT: To examine the effect of rimonabant on neurocognitive impairments in people with schizophrenia. Participants entered a 16-week double-blind, placebo-controlled, randomized clinical trial. A neurocognitive battery was administered at baseline and end of study. In comparison to rimonabant (20mg/day), placebo-treated participants exhibited a significant improvement on the Repeatable Battery for the Assessment of Neuropsychological Status total score. In contrast, rimonabant was associated with significant improvement on a probabilistic learning task. There were no other significant treatment effects. Rimonabant did not improve global cognitive functioning, but did improve a specific learning deficit based on response to positive feedback.Schizophrenia Research 12/2011; 134(2-3):207-10. DOI:10.1016/j.schres.2011.11.009 · 4.43 Impact Factor